List of Excipients in Branded Drug VELETRI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actelion Pharmaceuticals US Inc	VELETRI	epoprostenol	66215-403	ARGININE
Actelion Pharmaceuticals US Inc	VELETRI	epoprostenol	66215-403	SODIUM HYDROXIDE
Actelion Pharmaceuticals US Inc	VELETRI	epoprostenol	66215-403	SUCROSE

VELETRI Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

VELETRI is a lyophilized epoprostenol sodium injection for continuous intravenous treatment of pulmonary arterial hypertension. Its commercial differentiation depends less on the active ingredient than on excipient-enabled stability, reconstitution performance, storage flexibility, and compatibility with ambulatory infusion systems. The principal opportunity is to improve the delivery package around epoprostenol rather than pursue a simple excipient substitution.

What is VELETRI and how does its formulation work?

VELETRI contains epoprostenol sodium, a short-acting prostacyclin analogue that requires continuous infusion because of its very short plasma half-life. The product is supplied as a sterile lyophilized powder in single-dose vials and is reconstituted before dilution and intravenous administration.[1]

The labeled excipient system includes:

Formulation element	Function
Glycine	Bulking agent and stabilizer during lyophilization
Mannitol	Bulking agent and cake-forming excipient
Sodium chloride	Tonicity adjustment
Sodium hydroxide	pH adjustment
Arginine or alkaline formulation components, depending on presentation and market	pH and stability control

The high-pH formulation is central to product performance. Epoprostenol is chemically unstable in aqueous solution, and alkaline conditions materially improve stability after reconstitution. The formulation therefore uses excipients and pH control as an integrated stability system rather than as independent ingredients.

VELETRI is administered through an infusion pump and an indwelling central venous catheter in many patients. Product performance is consequently tied to the entire drug-delivery system, including diluent, reservoir, tubing, filters, connectors, and pump programming.

What excipients protect VELETRI stability?

VELETRI’s principal excipient strategy is based on four technical requirements:

1. Maintaining an alkaline pH after reconstitution.
2. Producing a robust lyophilized cake.
3. Limiting degradation during refrigerated and room-temperature storage.
4. Maintaining compatibility with prolonged infusion-system contact.

The formulation has commercial value because the product does not behave like a conventional short-use injectable. The reconstituted and diluted solutions may remain in use for extended periods, subject to the prescribing information’s storage and administration conditions.[1]

Why pH is commercially important

Epoprostenol degrades rapidly under less favorable aqueous conditions. A high-pH environment reduces the rate of hydrolytic degradation and extends the usable period of prepared solutions. This creates a formulation tradeoff:

• Higher pH can improve chemical stability.
• Strongly alkaline solutions can increase risks related to local tolerability, container compatibility, tubing materials, and accidental exposure.
• Buffer selection can affect precipitation, osmolality, extractables, and pump-system compatibility.

A competing formulation that achieves comparable stability at a lower pH could have commercial value if it reduces handling concerns or expands compatibility with infusion equipment.

Why mannitol and glycine matter

Mannitol and glycine are conventional lyophilization excipients with different physical roles. Mannitol can create a strong, visually acceptable cake and contribute to formulation bulk. Glycine can support cake structure and may influence crystallization, residual moisture, and reconstitution time.

The commercial opportunity is not necessarily to replace either excipient. It may be to optimize the ratio, crystallization behavior, residual moisture profile, and vial fill weight to improve:

• Reconstitution speed.
• Cake appearance.
• Batch-to-batch uniformity.
• Shipping robustness.
• Long-term stability.
• Manufacturing yield.

Any change must preserve the product’s high-pH environment and avoid introducing new degradation pathways.

What formulations are protected by VELETRI’s product profile?

VELETRI’s product profile protects several practical attributes even when the active ingredient is no longer commercially differentiated by composition alone.

Lyophilized powder

The lyophilized presentation supports storage, transport, and reconstitution. A generic or follow-on product must demonstrate suitable control of:

• Reconstitution time.
• Visible and subvisible particles.
• Residual moisture.
• Sterility.
• Container-closure integrity.
• Reconstituted concentration.
• Stability after dilution.

A lyophilization cycle that consistently produces a low-moisture, mechanically stable cake can be a manufacturing advantage. It can also reduce vial breakage, rework, and inspection rejects.

Diluent strategy

The diluent is a major commercial variable. A product may use sterile water, a dedicated alkaline diluent, or another labeled vehicle. A dedicated diluent can reduce preparation errors and improve stability, but it adds packaging, supply-chain, and regulatory complexity.

Potential commercial formats include:

Format	Commercial benefit	Main barrier
Single-dose vial plus diluent vial	Familiar hospital workflow	Multiple preparation steps
Dual-chamber vial	Faster reconstitution and fewer manipulations	Device development and regulatory burden
Ready-to-use bag	Lower preparation burden	Shorter shelf-life and cold-chain requirements
Pharmacy-compounded premix	Lower bedside workload	Compounding standards and stability validation
Prefilled infusion reservoir	Better ambulatory convenience	Container and pump compatibility

A ready-to-use format could be attractive in high-volume pulmonary hypertension centers, but the stability requirement is demanding. The product must maintain potency and impurity control throughout storage and administration.

How strong is the VELETRI excipient and formulation estate?

The strongest protection around VELETRI is likely to reside in formulation know-how, manufacturing controls, stability data, and delivery-system integration rather than in broad ownership of the excipients themselves. Glycine, mannitol, sodium chloride, and sodium hydroxide are established pharmaceutical ingredients and are difficult to protect as standalone composition claims.

Potentially valuable formulation claim categories include:

• Epoprostenol at a defined concentration and alkaline pH.
• Specific excipient ratios.
• Stabilized aqueous epoprostenol compositions.
• Lyophilized cakes with defined residual moisture.
• Reconstituted solutions with specified stability periods.
• Diluted solutions compatible with particular infusion systems.
• Container materials that limit adsorption or extractables.
• Methods for reducing degradation during continuous infusion.
• Manufacturing processes that control polymorph, moisture, or degradation products.

The commercial strength of these claims depends on claim scope, expiration, prosecution history, and whether a competitor can design around the formulation. Publicly available FDA labeling establishes VELETRI’s formulation and administration requirements, but the FDA label alone does not establish the full scope of any patent estate.[1]

When does VELETRI lose exclusivity?

VELETRI was approved by the FDA in 2008 under NDA 022260.[1] Its original statutory market exclusivity period has expired. The relevant competitive question is therefore patent and regulatory protection, not remaining new-drug exclusivity.

Protection category	VELETRI position
FDA approval	Approved in 2008
New-drug exclusivity	Expired
Orphan-drug exclusivity	Any original period would have expired
Active ingredient	Epoprostenol is an established active ingredient
Biosimilar pathway	Not applicable; VELETRI is a small-molecule drug
Generic pathway	ANDA pathway is potentially available
Formulation patents	Must be assessed against current patent records
Method-of-use patents	May remain relevant if listed or otherwise enforceable
Device and delivery patents	May affect commercial substitution without blocking drug approval

A current Orange Book review is necessary to determine whether any VELETRI patents remain listed for the specific NDA and whether a Paragraph IV certification could trigger litigation. The presence of an approved branded product does not by itself indicate an active patent barrier.

What generic entry risks exist for VELETRI?

Generic entry risk is material because epoprostenol is a small molecule and the active ingredient is established. The main obstacles are technical and commercial:

• Demonstrating pharmaceutical equivalence.
• Matching concentration and dosage form.
• Establishing suitable stability after reconstitution and dilution.
• Validating container-closure integrity.
• Demonstrating compatibility with infusion devices.
• Controlling degradation products.
• Supporting safe hospital preparation instructions.
• Building reliable supply for a specialty injectable.

A Paragraph IV challenge could target listed formulation or method-of-use patents. If no blocking patents remain, an ANDA applicant could pursue approval through a standard abbreviated pathway. The practical launch date would then depend on FDA review, patent certification, litigation, settlement terms, and commercial manufacturing readiness.

Which companies are challenging VELETRI?

No broadly established, high-profile VELETRI Paragraph IV litigation should be assumed without a current review of FDA, court, and Orange Book records. The more immediate competitive threat is likely to come from existing epoprostenol products and therapeutic substitutes rather than from a single litigation event.

How does VELETRI compare with competing pulmonary hypertension drugs?

VELETRI competes with other prostacyclin-pathway therapies, including Flolan, generic epoprostenol, treprostinil products such as Remodulin and Tyvaso, and iloprost products in relevant markets.

Product	Active ingredient	Administration	Formulation opportunity
VELETRI	Epoprostenol sodium	Continuous IV infusion	Stability, diluent, premix, pump compatibility
Flolan	Epoprostenol sodium	Continuous IV infusion	Cold-chain and preparation optimization
Generic epoprostenol	Epoprostenol sodium	Continuous IV infusion	Cost reduction and supply reliability
Remodulin	Treprostinil	Subcutaneous or IV infusion	Concentration, device, and reduced preparation burden
Tyvaso	Treprostinil	Inhaled	Device usability and formulation performance
Iloprost products	Iloprost	Inhaled or other regional presentations	Delivery-device and dosing convenience

VELETRI’s key product advantage is its room-temperature handling profile under labeled conditions compared with older epoprostenol formulations that impose more demanding storage or preparation requirements. Its commercial weakness is the continued need for continuous infusion and intensive catheter management.

What excipient opportunities have the highest commercial value?

1. Ready-to-use epoprostenol solutions

A stable, commercially manufactured solution that can be used without bedside reconstitution could reduce preparation errors and pharmacy labor. The product would need validated stability in an infusion bag or cartridge and compatibility with common pumps and tubing.

2. Extended room-temperature stability

Improving stability beyond current labeled handling periods could support home care, emergency transport, and hospital inventory management. This opportunity may involve:

• Alternative buffers.
• Chelating agents.
• Antioxidant systems.
• Oxygen-control packaging.
• Low-adsorption containers.
• Improved headspace management.

Each excipient must be evaluated for toxicity, compatibility, extractables, and impact on degradation products.

3. Higher-concentration presentations

Higher concentration could reduce infusion volume and reservoir changes, particularly for patients requiring high doses. The formulation challenge is maintaining solubility, chemical stability, acceptable osmolality, and pump accuracy.

4. Dual-chamber and closed-system delivery

A vial or cartridge that separates dry epoprostenol from diluent until use could simplify preparation while preserving shelf-life. Closed-system designs could reduce microbial contamination risk and improve handling in outpatient settings.

5. Low-sorption infusion materials

Epoprostenol may interact with tubing, reservoirs, and other contact materials. Low-binding polymers, surface treatments, and validated tubing sets could become differentiated products, particularly if they reduce dose loss or improve delivered-dose consistency.

6. Pharmacy-compounded stability platforms

Specialty pharmacies and hospital compounding centers may value validated premix systems with defined beyond-use periods. The opportunity is strongest where the supplier can combine formulation, sterile manufacturing, stability data, and standardized labeling.

What manufacturing and IP barriers affect commercial entry?

The most important manufacturing barriers are process control and stability validation. A competitor must control:

• Lyophilization cycle parameters.
• Residual moisture.
• Alkaline pH.
• Degradation impurities.
• Sterile filtration or aseptic filling.
• Vial and stopper compatibility.
• Reconstitution uniformity.
• Infusion-device contact performance.

The most defensible intellectual property may involve the combination of formulation and delivery system. A patent covering a generic excipient combination is less durable than one covering a specific stability profile, container system, or use condition that is difficult to replicate.

Trade secrets also have value. These may include lyophilization cycle design, pH adjustment sequence, mixing order, hold times, impurity-control specifications, and packaging conditions. Such know-how can delay competitors even where patent protection is weak.

What is the FDA regulatory status of VELETRI?

VELETRI is an FDA-approved prescription drug for intravenous infusion in pulmonary arterial hypertension.[1] It is not a biologic and therefore does not create conventional biosimilar risk. Follow-on products would generally be evaluated through the ANDA pathway if they meet the applicable requirements for pharmaceutical equivalence and bioequivalence, although injectable products may require extensive quality, compatibility, and stability documentation.

A reformulated product with a new delivery device, new concentration, or materially different clinical use may require a different regulatory strategy, potentially including a supplemental NDA or a new NDA depending on the extent of the change.

What is the revenue exposure to VELETRI competition?

Revenue exposure is concentrated in specialty pulmonary hypertension markets rather than broad primary care. Commercial risk depends on:

• Hospital formulary placement.
• Specialty-pharmacy distribution.
• Contract pricing.
• Availability of generic epoprostenol.
• Patient transition costs.
• Infusion-pump compatibility.
• Physician confidence in stability and supply.
• The cost of catheter and home-infusion support.

A lower-priced generic could pressure vial pricing quickly, but branded VELETRI may retain share if it offers stronger supply reliability, easier preparation, or better compatibility with established hospital protocols.

Key Takeaways

• VELETRI’s value is driven by epoprostenol stability, alkaline pH control, lyophilization quality, and infusion-system compatibility.
• Glycine, mannitol, sodium chloride, and pH-adjusting agents form the core excipient framework described in the product labeling.
• The principal commercial opportunities are ready-to-use solutions, higher concentrations, dual-chamber packaging, extended room-temperature stability, and low-sorption delivery systems.
• VELETRI’s original FDA exclusivity has expired, and biosimilar risk does not apply because epoprostenol is a small molecule.
• Generic entry risk is technically manageable but depends on stability, sterile manufacturing, device compatibility, and reliable specialty distribution.
• The strongest defensible assets may combine formulation claims, container systems, delivery devices, manufacturing know-how, and validated stability data.

FAQs

Can VELETRI use standard sterile water for reconstitution?

The permitted diluent and preparation method must follow the current VELETRI prescribing information. Diluent selection affects pH, stability, and allowable storage time.[1]

Is mannitol in VELETRI a patentable excipient?

Mannitol itself is a widely used pharmaceutical excipient. Patent value would more likely arise from a defined epoprostenol formulation, ratio, process, or stability result than from mannitol alone.

Could a generic manufacturer sell epoprostenol in a prefilled syringe?

A prefilled syringe would require evaluation of concentration, stability, syringe materials, extractables, sterility, dosing accuracy, and administration compatibility. It could require a regulatory pathway different from a conventional ANDA depending on the product design.

Does VELETRI have biosimilar competition?

No. VELETRI contains epoprostenol sodium, a small-molecule active ingredient. Competitive products would generally be generics or other small-molecule pulmonary hypertension therapies.

Which excipient innovation is most likely to improve VELETRI adherence?

A stable, ready-to-use or simplified-reconstitution presentation has the clearest potential to reduce preparation burden. The commercial value would depend on maintaining labeled stability and compatibility with home infusion pumps.

References

1. U.S. Food and Drug Administration. (2024). VELETRI (epoprostenol sodium) for injection: Prescribing information. GlaxoSmithKline LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.

3. United States Pharmacopeia. (2024). General chapter <1207>: Package integrity evaluation. United States Pharmacopeial Convention.